The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

Abstract Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Inflammatory bowel diseases 2018-01, Vol.24 (2), p.394-401
Hauptverfasser:	Macaluso, Fabio Salvatore, Sapienza, Chiara, Ventimiglia, Marco, Renna, Sara, Rizzuto, Giulia, Orlando, Rosalba, Di Pisa, Marta, Affronti, Marco, Orlando, Emanuele, Cottone, Mario, Orlando, Ambrogio
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use Adult Antibodies, Monoclonal - therapeutic use C-Reactive Protein - analysis Databases, Factual Drug Administration Schedule Drug Therapy, Combination - adverse effects Female Humans Immunosuppressive Agents - administration & dosage Inflammatory Bowel Diseases - drug therapy Infliximab - therapeutic use Male Middle Aged Prospective Studies Remission Induction Treatment Outcome Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!